# Bill & Melinda Gates Foundation

> Bill & Melinda Gates Foundation is a VC fund backing Biotechnology. See 353 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 353
- Last investment: Jun 2026
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/bill-&-melinda-gates-foundation
- X (Twitter): http://twitter.com/gatesfoundation
- Website: http://www.gatesfoundation.org
- Facebook: http://www.facebook.com/billmelindagatesfoundation

Bill & Melinda Gates Foundation is a VC fund in New York focused on Biotechnology and Health Care. The Bill & Melinda Gates Foundation is a grant-making foundation that supports initiatives in education, world health and population, and community giving in the Pacific Northwest. In its local region, the foundation promotes strategies and programs that help low income families.The Bill & Melinda Gates Foundation was co-founded by BillGates and Melinda Gates in 2000 and is based in Seattle, Washington, with regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. Its trustees are Bill and Melinda Gates, and Warren Buffett.

## Contacts

5 contacts available for Bill & Melinda Gates Foundation. Shizune tracks 23 team members at Bill & Melinda Gates Foundation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bill-melinda-gates-foundation?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Grant | $500k–$14M |
| Series A | $8.1M–$60M |
| Series B | $8M–$85M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 125 | 35% |
| Health Care | 83 | 24% |
| Medical | 48 | 14% |
| Pharmaceutical | 41 | 12% |
| Therapeutics | 26 | 7% |

159 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 176 | 50% |
| Series A | 20 | 6% |
| Series B | 12 | 3% |
| Seed | 11 | 3% |
| Series C | 10 | 3% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 115 | 33% |
| United Kingdom | 17 | 5% |
| India | 10 | 3% |
| Canada | 9 | 3% |
| The Netherlands | 7 | 2% |

36 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bill Gates | Co-Chairman of the Board | 96 | https://shizune.co/investors/profile/bill-gates |
| Bill Gates | Co-Chairman of the Board | 95 | https://shizune.co/investors/profile/william-gates-sr |
| Brian Arbogast | Director of the Water, Sanitation & Hygiene Program | 1 | https://shizune.co/investors/profile/brian-arbogast |
| Chris Karp | Director, Global Health Discovery & Translational Sciences | 2 | https://shizune.co/investors/profile/chris-karp |
| Dan Hartman | Director, Integrated Development; Interim Director, Malaria. Global Health | 0 | https://shizune.co/investors/profile/dan-hartman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Leyden Labs | Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $45.4M |  | Jun 25, 2026 |  |
| Replicate Bioscience | Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) technology to enhance the effectiveness of RNA-based therapeutics beyond traditional mRNA approaches. Its platform is designed to deliver stronger biological activity, more durable immune responses, and an improved therapeutic index. The company’slead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology. | $3M | Grant | Jun 19, 2026 |  |
| Nortiva Bio | Nortiva Bio is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, that is pioneering long-acting oral therapies using its proprietary LYNX™ drug delivery platform. | $5M | Grant | Jun 18, 2026 |  |
| Remidio Innovative Solutions | Remidio is engaged in designing & developing Smart, Innovative & Disruptive Imaging Technologies in Vision Care, using a product development approach called “Design Thinking”.As part of the Design Thinking process, Remidio takes into account different facets of a customer’s experience with a product, as part of its overall productdesign approach, with the intent of inventing a new customer experience with the product.Customers can be an amazing resource to glean insight and understanding, but they are generally not able to articulate their latent and anticipated needs. Remidio hence focuses on making quick functional prototypes, that can then be given to the customer to understand these latent needs while observing their use of the prototypes.Founded by professionals with a passion for product innovation, Remidio is currently focussed on creating game changing products and solutions in the ophthalmology space.We look at constraints posed by a developing nation context- infrastructure, skilled resources and affordable pricing as an opportunity to innovate.We bring to market very high quality products that are reliable and extremely simple to use. |  | Grant | Jun 10, 2026 |  |
| Converge Bio | Converge Bio integrates Generative AI with biological data. Converge Bio mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages. | $2.5M | Grant | May 27, 2026 |  |
| Evotec | Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases. | $9.9M | Grant | Apr 30, 2026 |  |
| Sibel Health | Sibel Health develops a neonatal epidermal system designed for wireless vital signs monitoring. It develops soft, flexible sensors that are powered by advanced analytics, operated by best-in-class software, and integrated with the cloud-optimized for artificial intelligence and machine learning.The company was founded in 2018 and is headquarteredin Niles, Illinois. | $5M | Grant | Apr 09, 2026 |  |
| Tessera Therapeutics | Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. |  | Grant | Mar 23, 2026 |  |
| Rainbow Crops | Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties. | $7M | Grant | Mar 04, 2026 |  |
| Plasmaleap | Plasmaleap is a plasma technology company that manufactures and sells zero-emissions chemical reactors designed for industrial and energy applications. The company develops reactor systems that use plasma processes to enable chemical production and transformation without relying on conventional combustion methods. Its technology supports sectorssuch as clean fuels, chemical manufacturing, and materials processing by offering electrified reactor solutions that can be integrated into existing industrial workflows. Plasmaleap designs modular systems that allow operators to deploy plasma reactors for on-site production and conversion of feedstocks using electricity as the primary energy input. The company also provides engineering support and technical integration services to help customers incorporate its reactor technology into commercial operations. Through its plasma-based approach, Plasmaleap focuses on enabling chemical processes that align with decarbonization and emissions reduction objectives across multiple industries. | $21.3M | Series A | Mar 02, 2026 |  |

10 of 353 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 5 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 5 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [Nomura](https://shizune.co/investors/profile/nomura) — VC Fund, 4 deals together
- [Oikocredit International](https://shizune.co/investors/profile/oikocredit-international) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [Launch Africa](https://shizune.co/investors/profile/launch-africa) — VC Fund
- [Raba Partnership](https://shizune.co/investors/profile/rabba-capital) — VC Fund
- [Women Entrepreneurship for Africa](https://shizune.co/investors/profile/women-entrepreneurship-for-africa) — VC Fund

## Featured in investor lists
- [Finance VC Funds in India](https://shizune.co/investors/finance-vc-funds-india)
- [Health Care VC Funds in Africa](https://shizune.co/investors/health-care-vc-funds-africa)
- [Transportation VC Funds in Africa](https://shizune.co/investors/transportation-vc-funds-africa)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotechnology Investors in Argentina](https://shizune.co/investors/biotechnology-investors-argentina)

## FAQ

### What does Bill & Melinda Gates Foundation invest in?

Bill & Melinda Gates Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Series A stage. Most of the 353 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Bill & Melinda Gates Foundation's check size?

Bill & Melinda Gates Foundation typically joins rounds of $500k–$14M at Grant, $8.1M–$60M at Series A and $8M–$85M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bill & Melinda Gates Foundation participates in.

### How do I contact Bill & Melinda Gates Foundation?

Public channels for Bill & Melinda Gates Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bill & Melinda Gates Foundation?

The team at Bill & Melinda Gates Foundation includes Bill Gates (Co-Chairman of the Board), Bill Gates (Co-Chairman of the Board) and Brian Arbogast (Director of the Water, Sanitation & Hygiene Program), among 23 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co